Brief Summary
The most common types of acutenew, recent, comes with an urgent or significant sense, is sudden, sharp leukaemiacancer of blood and/or blood forming tissues are acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). AML is a heterogenous clonal disorder of haemopoietic progenitor cellsthe basic structural and functional unit of all living things and the most common and severe malignantcancerous, may grow and spread to other areas of the body leukemia in adults and is responsible for the highest mortality from leukemia. ALL is a neoplasm characterized by the growth of malignant lymphoblasts of the B or T lineage, leading to an inhibition of proliferation of the normal bloodthe red bodily fluid that transports oxygen and other nutrients around the body cell lineages.
The primary objectives of this study are investigating the safety, tolerability, and the MTD of LBS-007. The secondary objectives are to assess the efficacy and to determine the pharmacokinetics (PK) of LBS-007. The exploratory objective is to study and correlate the changes in surrogate biomarkers in response to treatment.
Intervention / Treatment
- Drug: LBS-007
Inclusion Criteria:
- Male or female subjects greater than 18 years old, inclusive.
- Pathologically confirmed diagnoses of Relapsed or resistant AML or ALL.
- Patients who are ineligible for standard therapies that are anticipated to result in durable remissiona reduction or absence of symptoms in disease, can be partial or complete or cureno evidence of disease; complete cancer remission, or who have no known therapy options of documented benefit.
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status 0 to 2.